Global Burden, Regional Differences, Trends, and Health Consequences of Medication Nonadherence for Hypertension During 2010 to 2020: A Meta‐Analysis Involving 27 Million Patients
Eric K. P. Lee,Paul Poon,Benjamin H. K. Yip,Yacong Bo,Meng‐Ting Zhu,Chun‐Pong Yu,Alfonse C. H. Ngai,Martin C. S. Wong,Samuel Y. S. Wong
DOI: https://doi.org/10.1161/JAHA.122.026582
2022-09-04
Abstract:Background Nonadherence to antihypertensive medications is the leading cause of poor blood pressure control and thereby cardiovascular diseases and mortality worldwide. Methods and Results We investigated the global epidemiology, regional differences, and trend of antihypertensive medication nonadherence via a systematic review and meta‐analyses of data from 2010 to 2020. Multiple medical databases and clinicaltrials.gov were searched for articles. Observational studies reporting the proportion of patients with anti‐hypertensive medication nonadherence were included. The proportion of nonadherence, publication year, year of first recruitment, country, and health outcomes attributable to antihypertensive medication nonadherence were extracted. Two reviewers screened abstracts and full texts, classified countries according to levels of income and locations, and extracted data. The Joanna Briggs Institute prevalence critical appraisal tool was used to rate the included studies. Prevalence meta‐analyses were conducted using a fixed‐effects model, and trends in prevalence were analyzed using meta‐regression. The certainty of evidence concerning the effect of health consequences of nonadherence was rated according to Grading of Recommendations, Assessment, Development and Evaluations. A total of 161 studies were included. Subject to different detection methods, the global prevalence of anti‐hypertensive medication nonadherence was 27% to 40%. Nonadherence was more prevalent in low‐ to middle‐income countries than in high‐income countries, and in non‐Western countries than in Western countries. No significant trend in prevalence was detected between 2010 and 2020. Patients with antihypertensive medication nonadherence had suboptimal blood pressure control, complications from hypertension, all‐cause hospitalization, and all‐cause mortality. Conclusions While high prevalence of anti‐hypertensive medication nonadherence was detected worldwide, higher prevalence was detected in low‐ to middle‐income and non‐Western countries. Interventions are urgently required, especially in these regions. Current evidence is limited by high heterogeneity. Registration URL: www.crd.york.ac.uk/prospero/; Unique identifier: CRD42021259860. Nonstandard Abbreviations and Acronyms MMAS Morisky Medication Adherence Scale MPR medication possession ratio WHO World Health Organization Clinical Perspective What Is New? Anti‐hypertensive medication nonadherence was common globally (27%–40%), was more prevalent in low‐ to middle income and non‐Western countries, and did not improve between 2010 and 2020. What Are the Clinical Implications? Policymakers and clinicians should incorporate validated methods (eg, validated questionnaires, medication procession ratio, pill counting, electronic pills or pillbox, and biochemical detection by drug assays) into health care systems to routinely detect anti‐hypertensive medication nonadherence. Once detected, clinicians could conceptualize the reasons for nonadherence, using the World Health Organization model, and manage them accordingly. Medication adherence is defined as the "extent to which patients take their medication as prescribed." 1 , 2 Although hypertension is one of the most common chronic conditions and a leading cause of death globally, 3 medication nonadherence among patients with hypertension is highly prevalent. Up to 50% of patients stop taking their prescribed antihypertensive medications within 1 year of initiation. 4 The high prevalence of antihypertensive medication nonadherence has contributed to poor blood pressure (BP) control worldwide. Accordingly, optimal control of BP is attained in less than one‐third and one‐tenth of patients with hypertension in high‐income and low‐ to middle‐income countries, respectively. 1 , 3 This poor control has consequently led to a high global burden of cardiovascular diseases, chronic kidney disease, dementia, and mortality. The World Health Organization (WHO) has provided a conceptual framework to explain the multifactorial reasons underlying antihypertensive medicati -Abstract Truncated-